5 Sep 2012 07:00
05 September 2012
Instem plc
("Instem" or the "Company")
Notice of Results
Instem (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, will be announcing its interim results for the six months ended 30 June 2012 on Wednesday 19th September 2012.
Management will be hosting a presentation for analysts on the day of results. Analysts who wish to attend the presentation should register their interest with Fiona Conroy, contactable at f.conroy@newgatethreadneedle.com or 020 7653 9847.
For further information, please contact:
Instem plc | +44 (0) 1785 825 600 |
Phil Reason, CEO | |
Nigel Goldsmith, CFO | |
N+1 Brewin (Nominated Adviser & Broker) | +44 (0) 20 3201 3710 |
Aubrey Powell | |
Luke Boyce | |
Newgate Threadneedle | +44 (0) 20 7653 9850 |
Caroline Evans-Jones | |
Fiona Conroy | |
About Instem plc
Instem (AIM: INS.L) is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.
Instem has over 130 customers in North America, Europe, China, India and Japan, including sixteen of the top twenty pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Group employs over 110 people in seven offices in the US, UK, China and India; and a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software.
To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/.
INS.L (INS)